Sonnet BioTherapeutics Holdings, Inc. stock is up 31.36% since 30 days ago. The next earnings date is Dec 22, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 18 December’s closed higher than November. 100% of analysts rate it a buy.
Sonnet BioTherapeutics Holdings, Inc. develops platform for biologic medicines of single or bispecific action. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer.